[Curative effect of interleukin 11 on chronic idiopathic thrombocytopenic purpura].
The aim of this study was to investigate the circulating levels of IL-11 in the patients with chronic idiopathic thrombocytopenic purpura (CITP), and its significance, and to evaluate the curative effect of rhIL-11 on CITP. The level of IL-11 in patients with CITP was determined by ELISA before and after treatment, respectively. 1.5 mg of rhIL-11 were injected subcutaneously, once a day, continuously for 14 days as one course, treatment time 1 - 2 courses as total. The results showed that the higher blood IL-11 level was found in CITP patients than that in controls (P < 0.01) and during the course of treatment the number of platelets in peripheral blood of patients with CITP parallelled to the level of IL-11. The platelet counts were obviously increased in all CITP patients after rhIL-11 treatment. It is concluded that the serum level of IL-11 in patients is correlated to the number of platelets in patients. rhIL-11 can be used as an effective treatment for CITP.
Zhang
Qiu-Rong
QR
Department of Hematology, The Second Affiliated Hospital, Xuzhou Medical Collage, Xuzhou 221006, China. xzqiurong@tom.com
Wu
De-Pei
DP
Chen
Ling-Song
LS
Cao
Ruo-Nan
RN
D000293:Adolescent; D000328:Adult; D000368:Aged; D002908:Chronic Disease; D005260:Female; D006801:Humans; D017370:Interleukin-11 / Q000097:blood / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010976:Platelet Count; D016553:Purpura, Thrombocytopenic, Idiopathic / Q000188:drug therapy*; D011994:Recombinant Proteins / Q000627:therapeutic use; D016896:Treatment Outcome
D017370:Interleukin-11; D011994:Recombinant Proteins